Molecular and Clinical Repercussions of GABA Transporter 1 Variants Gone Amiss: Links to Epilepsy and Developmental Spectrum Disorders

Florian P. Fischer¹,²†, Ameya S. Kasture³†, Thomas Hummel³ and Sonja Sucic¹*

¹Institute of Pharmacology, Medical University of Vienna, Vienna, Austria, ²Department of Epileptology and Neurology, University of Aachen, Aachen, Germany, ³Department of Neuroscience and Developmental Biology, University of Vienna, Vienna, Austria

The human γ-aminobutyric acid (GABA) transporter 1 (hGAT-1) is the first member of the solute carrier 6 (SLC6) protein superfamily. GAT-1 (SLC6A1) is one of the main GABA transporters in the central nervous system. Its principal physiological role is retrieving GABA from the synapse into neurons and astrocytes, thus swiftly terminating neurotransmission. GABA is a key inhibitory neurotransmitter and shifts in GABAergic signaling can lead to pathological conditions, from anxiety and epileptic seizures to schizophrenia. Point mutations in the SLC6A1 gene frequently give rise to epilepsy, intellectual disability or autism spectrum disorders in the afflicted individuals. The mechanistic routes underlying these are still fairly unclear. Some loss-of-function variants impair the folding and intracellular trafficking of the protein (thus retaining the transporter in the endoplasmic reticulum compartment), whereas others, despite managing to reach their bona fide site of action at the cell surface, nonetheless abolish GABA transport activity (plausibly owing to structural/conformational defects). Whatever the molecular culprit(s), the physiological aftermath transpires into the absence of functional transporters, which in turn perturbs GABAergic actions. Dozens of mutations in the kin SLC6 family members are known to exhort protein misfolding. Such events typically elicit severe ailments in people, e.g., infantile parkinsonism-dystonia or X-linked intellectual disability, in the case of dopamine and creatine transporters, respectively. Flaws in protein folding can be rectified by small molecules known as pharmacological and/or chemical chaperones. The search for such apt remedies calls for a systematic investigation and categorization of the numerous disease-linked variants, by biochemical and pharmacological means in vitro (in cell lines and primary neuronal cultures) and in vivo (in animal models). We here give special emphasis to the utilization of the fruit fly Drosophila melanogaster as a versatile model in GAT-1-related studies. Jointly, these approaches can portray indispensable insights into the molecular

Abbreviations: 4-PBA: 4-phenylbutyric acid; ADHD: attention deficit hyperactivity disorder; BGT-1: betaine/GABA transporter 1; CRT-1: creatine transporter 1; DAT: dopamine transporter; DTDS: dopamine transporter deficiency syndrome; ER: endoplasmic reticulum; ERAD: ER associated degradation; GABA: γ-aminobutyric acid; GAT-1: GABA transporter 1; GLUT-1: glucose transporter 1; GLYT-2: glycine transporter 2; HSP: heat shock proteins; ID: intellectual disability; iPSC: induced pluripotent stem cells; KO: knockout; NET: norepinephrine transporter; SERT: serotonin transporter; SLC6: solute carrier 6; SNARE: soluble NSF attachment protein (SNAP) receptor; TM: transmembrane (domain); VGAT: vesicular GABA transporter.
factors underlying epilepsy, and ultimately pave the way for contriving efficacious therapeutic options for patients harboring pathogenic mutations in hGAT-1.

**Keywords**: autism, *Drosophila melanogaster*, epilepsy, gamma-aminobutyric acid (GABA), GABA transporter 1, intellectual disability, protein folding, transporter disease variants

**ON THE RUDIMENTS OF GABA AND GATS**

The γ-aminobutyric acid (GABA) is a non-proteinogenic amino acid, first detected in the brain tissue in the 1950s (Awapara et al., 1950; Roberts and Frankel, 1950). It is known to play diverse physiological roles as a metabolite, neurotransmitter and neurotrophin (Waagepetersen et al., 1999). GABA is the principal mammalian inhibitory neurotransmitter, essential for counterbalancing neuronal excitability. Alterations in GABAergic signaling have been implicated in seizure generation (Roth and Draguhn, 2012; Kang, 2017). The GABA transporter 1 (GAT-1), encoded by the SLC6A1 gene, is one of the main GABA transporters in the brain. It is responsible for the reuptake of GABA from the synaptic cleft, constituting a core component of GABAergic signaling. Recent mutations discovered in the SLC6A1 gene have been linked to a range of neurodevelopmental disorders, including diverse epilepsy syndromes, intellectual disability (ID) and autism spectrum disorders (Goodspeed et al., 2020). The precise molecular culprits underlying the pathophysiological SLC6A1 mutations are as yet quite unknown. Recent experimental evidence suggests reduced or abolished GABA uptake function as a common feature underlying the disease mechanism (Mattison et al., 2018; Mermer et al., 2021). Additionally, some of the mutations likely trigger folding defects, leading to retention of GAT-1 proteins in the endoplasmic reticulum (ER) (Wang et al., 2020; Mermer et al., 2021). Diseases arising from folding-deficient variants of other solute carrier (SLC) 6 transporters are not without precedent: e.g., misfolded variants of the dopamine transporter (DAT, SLC6A3) and the creatine transporter 1 (CRT-1, SLC6A8) cause infantile/juvenile parkinsonism-dystonia and the creatine transporter deficiency syndrome, respectively (Farr et al., 2020; Bhat et al., 2021). Insights gained from studies of these closely related transporters may better our understanding of the molecular pathophysiology behind SLC6A1-related disorders, and considerably accelerate the development of novel precision medicine treatments.

**THE SUBFAMILY OF GABA TRANSPORTER PROTEINS**

The human genome encodes four isoforms of GATs, which are designated GAT-1 (SLC6A1), BGT-1 (betaine/GABA transporter 1, SLC6A12), GAT-2 (SLC6A13) and GAT-3 (SLC6A11). It should be noted that GATs in humans and rats share the same nomenclature, whereas the corresponding GATs in mice are named differently, i.e., GAT1, GAT2, GAT3 and GAT4, respectively (Schousboe et al., 2014). The physiological role of these high-affinity transport proteins is to regulate the extracellular levels of GABA during synaptic transmission and under basal conditions (Scimemi, 2014). The reported $K_m$ values for the human isoforms GAT-1, BGT-1, GAT-2 and GAT-3 are 11, 18.81, and 0.56 μM, respectively (Rowley et al., 2012). BGT-1 is also able to carry betaine, whereas GAT-2 and GAT-3 exhibit an additional capacity to transport taurine and β-alanine (Rowley et al., 2012).

The tissue expression atlas of GATs revealed that the predominant isoforms in the brain are GAT-1 and GAT-3, while GAT-2 and BGT-1 are found primarily in the liver and kidney (Zhou and Danbolt, 2013). GAT-1 is mainly localized to presynaptic GABAergic neurons and to a minor degree to distal astrocytic processes (Rowley et al., 2012). It is highly expressed in the cerebellum, basal ganglia, olfactory bulb, retina and interpeduncular nucleus (Scimemi, 2014). In contrast to GAT-1, GAT-3 is thought to be exclusively located on astrocytes (Zhou and Danbolt, 2013). It shows robust expression in the olfactory bulb, brainstem, thalamus and hypothalamus but only modest expression in the caudate-putamen, hippocampus, cerebral cortex and cerebellum (Minelli et al., 1996). In the brain, GAT-2 is present in the leptomeninges and ependyma, and to a lesser degree on cortical neurons and astrocytes (Conti et al., 1999). BGT-1 has only been detected in the leptomeninges (Zhou et al., 2012), cerebral cortex and hippocampus (Zhu and Ong, 2004).

**THE HUMAN GABA TRANSPORTER 1 IN THE SPOTLIGHT**

The human GAT-1 isoform, encoded on chromosome 3 (3p25.3), is composed of 599 amino acid residues, organized into twelve putative transmembrane (TM) segments, with cytoplasmic amino- and carboxyl-termini (Bennett and Kanner, 1997; Hoglund et al., 2005). It is predominantly localized to presynaptic terminals and to distal astrocytic processes (Minelli et al., 1995). GAT-1 is also found in cell bodies and dendrites for a short time period during cortical development (Yan et al., 1997). At some synapses in the cerebellum and hippocampus, the average membrane density of GAT-1 was estimated to be about 800–1,300/μm². Approximately 60% of the transporter molecules were shown to reside at the cell surface, whereas the remaining 40% seem to be located in the cytoplasmic regions of the cell (Chiu et al., 2002).

The translocation process of GABA via GAT-1 is electrogenic and coupled to the inward transport of two Na⁺ ions and one Cl⁻ ion. Accordingly, the translocation of one neutral GABA molecule is predicted to lead to a net influx of one positive charge (Scimemi, 2014). The functional role of GAT-1 has been
extensively studied in genetic mouse models (Jensen et al., 2003; Chiu et al., 2005; Cai et al., 2006; Liu et al., 2007a; Liu et al., 2007b; Xu et al., 2008; Cope et al., 2009). GAT-1 knockout (KO) mice show elevated ambient GABA levels, which cause an increase in GABA-mediated tonic conductance due to overstimulation of extrasynaptic GABAA-receptors. Moreover, GAT-1-deficient mice display a decreased quantal GABA release as well as a reduced presynaptic GABAB-receptor function. These findings imply that GAT-1 deficiency leads to an enhanced tonic and a reduced phasic inhibition (Jensen et al., 2003). GAT-1 KO mice also display some behavioral patterns (e.g. tremor, ataxia and nervousness) that phenocopy the clinical side effects of the GAT-1 inhibitor tiagabine (Chiu et al., 2005), which is used as an add-on therapy in the treatment of partial-onset seizures (LaRoche and Helmers, 2004). Besides tiagabine, several other selective GAT-1 inhibitors have been developed to date, e.g., CI-966, SKF89976 A and NO-711, which are lipophilic derivatives of either nipecotic acid or guvacine. In addition, numerous drugs have been identified as non-selective GAT inhibitors. These drugs include ß-alanine, betaine, (S)-SNAP-5114, (R)-EF1502, THPO, exo-THPO and NNC 05–2090 (Kristensen et al., 2011).

GAT-1 is regulated via multiple mechanisms including second messengers and protein-protein-interactions. These forms of regulation are thought to modulate the function of GAT-1 either by redistributing the transporter or by altering the GABA translocation rates (Chen et al., 2004). Activation of protein kinase C is associated with a down-regulation of GAT-1. In contrast, tyrosine phosphorylation has been shown to increase the surface expression of GAT-1 due to reduced internalization rates (Quick et al., 2004). Moreover, GAT-1 is regulated by extracellular GABA levels, which typically boosts cell surface expression of the transporter. Conversely, inhibitors of GAT-1 have been shown to decrease surface levels of GAT-1 (Bernstein and Quick, 1999). GAT-1 is also known to undergo regulation by the SNARE protein syntaxin 1A, which binds to the transporter´s amino-terminal region. This interaction promotes both an increase in cell surface expression and a decrease in GAT-1 protein turnover rates (Deken et al., 2000). Several groups have showed that GAT-1 forms oligomeric structures (Schmid et al., 2001; Moss et al., 2009). Although each monomer is able to translocate GABA independently (Soragna et al., 2005), oligomerization is a prerequisite for concentrative export from the ER compartment and subsequent trafficking to GATs’ eponymous site of action at the plasma membrane (Scholze et al., 2002).

THE CLINICAL SPECTRUM OF HUMAN GAT-1 DISEASE VARIANTS

Over recent years, a compendium of SLC6A1 mutations (Figure 1) have been associated with a range of neurodevelopmental disorders, including autism, variable degrees of ID and a spectrum of epilepsy syndromes (Table 1) (Carvill et al., 2015; Johannesen et al., 2018; Mattison et al., 2018; Goodspeed et al., 2020; Kahlen et al., 2021). Point mutations in SLC6A1 were first identified in patients suffering from epilepsy with myoclonic-atonic seizures (also known as Doose syndrome) (Carvill et al., 2015). This debilitating childhood-onset epilepsy syndrome is characterized by seizures of multiple types, such as myoclonic-atonic, atomic or generalized tonic-clonic seizures (Tang et al., 2020). Soon after, SLC6A1 variants were also reported in individuals afflicted with other forms of
### TABLE 1 | Human GAT-1 variants associated with neurological disorders.

| Variant | Associated Phenotype(s) | References |
|---------|-------------------------|------------|
| K36Efs*171 (de novo) | Early onset absence epilepsy, moderate ID, hypotonia | Johannesen et al. (2018) |
| R44Q (de novo) | Epilepsy with myoclonic-atactic seizures, mild ID, autistic features | Carvill et al. (2015) |
| R44W (de novo) | Epilepsy, autism spectrum disorder, hypotonia | Kahlen et al. (2021), Mermer et al. (2021) |
| D52E/V (inherited/AD) | Global developmental delay | Landrum et al. (2018), NCBI ClinVar ID 987287/987286 |
| F53S (inherited/AD) | Global developmental delay | Landrum et al. (2018), NCBI ClinVar ID 987288 |
| G63S | ID, developmental disorder | Liu et al. (2018) |
| L73F (de novo) | Epilepsy | Mermer et al. (2021) |
| G75R (de novo) | Epilepsy, movement disorder | Mattison et al. (2018) |
| G297R (de novo) | Epilepsy, language disorder, developmental delay, ID, autism spectrum disorder, hypotonia, movement disorder | Islam et al. (2018), Kahlen et al. (2021) |
| G360S/VfsX*14 (unknown) | Early onset absence epilepsy, moderate ID, hypotonia | Wang et al. (2016) |
| G299V (de novo) | Epilepsy with myoclonic-atactic seizures, ID, autism spectrum disorder, hypotonia | Kahlen et al. (2021) |
| A305T | Epilepsy, movement disorder, hypotonia | Mattison et al. (2018) |
| G111R (de novo) | Language disorder, developmental delay, hypotonia, movement disorder | Kahlen et al. (2021) |
| V123M (gonadal mosaic) | Epilepsy with myoclonic-atactic seizures, moderate ID, ADHD | Palmer et al. (2016) |
| A128V | Epilepsy with myoclonic-atactic seizures, mild to moderate ID | Johannesen et al. (2018) |
| G232V | Epilepsy, movement disorder, hypotonia | Rauch et al. (2012) |
| D52 E/V | Epilepsy with myoclonic-atactic seizures | Mermer et al. (2021) |
| R44Q (de novo) | Epilepsy, movement disorder, hypotonia | Liu et al. (2018) |
| G75R (de novo) | Epilepsy, movement disorder, hypotonia | Mermer et al. (2021) |
| G297R (de novo) | Epilepsy, movement disorder, hypotonia | Mattison et al. (2018) |
| G111R (de novo) | Language disorder, developmental delay, hypotonia, movement disorder | Kahlen et al. (2021) |
| V123M (gonadal mosaic) | Epilepsy with myoclonic-atactic seizures, moderate ID, ADHD | Palmer et al. (2016) |
| A128V | Epilepsy with myoclonic-atactic seizures, mild to moderate ID | Johannesen et al. (2018) |
| G232V | Epilepsy, movement disorder, hypotonia | Rauch et al. (2012) |
| D52 E/V | Epilepsy with myoclonic-atactic seizures | Mermer et al. (2021) |
| R44Q (de novo) | Epilepsy, movement disorder, hypotonia | Liu et al. (2018) |
| G75R (de novo) | Epilepsy, movement disorder, hypotonia | Mermer et al. (2021) |
| G297R (de novo) | Epilepsy, movement disorder, hypotonia | Mattison et al. (2018) |
| G234S (unknown) | Lennox-Gastaut syndrome, moderate ID | Cai et al. (2019) |
| W235R (unknown, adopted) | Absence epilepsy, moderate ID, autism spectrum disorder | Mattison et al. (2018) |
| L251P (de novo) | Language disorder, developmental delay, ID, hypotonia | Kahlen et al. (2021) |
| F270S (de novo) | Generalized epilepsy, mild ID, irritability, ADHD | Johannesen et al. (2018), Mattison et al. (2018) |
| I272del*4 (de novo) | Epilepsy with myoclonic-atactic seizures, moderate ID, bilateral upper extremity tremor, mild tandem gait, ataxia | Mattison et al. (2018) |
| A288M (de novo) | Lennox-Gastaut syndrome, developmental delay, ID, autism spectrum disorder | Cai et al. (2019) |
| A288V (inherited and de novo) | Epilepsy with myoclonic-atactic seizures, atypical benign epilepsy with centrotemporal spikes (evolving into a generalized epilepsy), mild to severe ID, autistic features, aggressive behavior | Sanders et al. (2012), Carvill et al. (2015), Johannesen et al. (2018) |
| G239R (de novo) | Epilepsy, language disorder, developmental delay, hypotonia | Kahlen et al. (2021) |
| F294del*5 (de novo) | Epilepsy with myoclonic-atactic seizures, moderate ID, attention deficit, mild ataxia | Johannesen et al. (2018) |
| S295L | Epilepsy, developmental delay, ID, autism spectrum disorder, hypotonia, movement disorder | Kahlen et al. (2021), Mermer et al. (2021) |
| G297R (de novo) | Epilepsy with myoclonic-atactic seizures, severe ID, autistic features, moderately severe tremor, aggressive behavior | Carvill et al. (2015) |
| G299V (de novo) | Autism spectrum disorder | Wang et al. (2016), Mermer et al. (2021) |
| A305T (unknown) | Epilepsy, language disorder, developmental delay, hypotonia | Kahlen et al. (2021), Mermer et al. (2021) |
| G307R (unknown) | Epilepsy, developmental delay, ID, hypotonia, Rett-like syndrome | Lucarello et al. (2016), Kahlen et al. (2021) |
| N310I (de novo) | ID, developmental disorder | Liu et al. (2018) |
| N3273 (de novo) | Epilepsy, language disorder, developmental delay, ID, autism spectrum disorder, hypotonia, movement disorder | Kahlen et al. (2021) |
| C329R (de novo) | Epilepsy with myoclonic-atactic seizures, mild ID, aggressive behavior | Mattison et al. (2018) |
| S331G (de novo) | Epilepsy, language disorder, developmental delay, ID, ADHD, hypotonia, movement disorder | Kahlen et al. (2021) |
| A334P (mosaic mother) | Epilepsy with myoclonic-atactic seizures, moderate ID | Carvill et al. (2015) |
| F339L (mosaic mother) | Autism spectrum disorder | Yuen et al. (2016) |
| F339L (mosaic mother) | Childhood absence epilepsy, epilepsy with myoclonic-atactic seizures, eyelid myoclonia with absences, generalized epilepsy, mild to severe ID and learning disabilities, autism spectrum disorder, aggressive behavior, ADHD, tremor, mild hypotonia, weak fine motor skills, ataxia | Johannesen et al. (2018) |
| A357V (de novo) | Epilepsy with myoclonic-atactic seizures, moderate ID, unsteady gait | Johannesen et al. (2018) |
| G360S/VfsX*14 (unknown) | Autism spectrum disorder | Wang et al. (2016) |
| P361T (de novo) | Generalized epilepsy, autism spectrum disorder | Wang et al. (2020), Mermer et al. (2021) |
| G362R (mosaic mother) | Lennox-Gastaut syndrome, temporal lobe epilepsy, moderate ID | Halvorsen et al. (2016), Johannesen et al. (2018) |
| F385L (de novo) | Epilepsy with myoclonic-atactic seizures, mild to moderate ID, autism spectrum disorder | Johannesen et al. (2018) |
| Q397* (de novo) | Epilepsy, autism spectrum disorder | Wang et al. (2016) |
| L408Wfs*26 (unknown) | Epilepsy, developmental delay, ADHD, hypotonia | Kahlen et al. (2021) |
| R419Afs*15 (unknown) | Epilepsy, developmental delay, ADHD, autism spectrum disorder, hypotonia, movement disorder | Kahlen et al. (2021) |
| Y445C (unknown) | Generalized epilepsy | Mattison et al. (2018) |
| G443D (de novo) | Epilepsy, developmental delay, autism spectrum disorder | Devries et al. (2020) |

(Continued on following page)
generalized epilepsies (e.g., childhood absence epilepsy) as well as in some patients with focal epilepsies (e.g., temporal lobe epilepsy) (Johannesen et al., 2018). Detailed data on seizure semiology revealed that absence, atonic and myoclonic seizures are the most frequently observed seizure types (Johannesen et al., 2018; Goodspeed et al., 2020; Kahen et al., 2021).

Apart from epilepsy, mild to pronounced cognitive impairment is another common hallmark of SLC6A1 variant carriers. In fact, almost all of the afflicted individuals display some degree of ID, mostly in the mild to moderate range (Johannesen et al., 2018; Goodspeed et al., 2020). A large fraction of the affected patients manifest behavioral problems, such as aggressive behavior/irritability, attention deficit, hyperactivity and autistic traits. Other reported clinical features include mild ataxia, unsteady gait, hypotonia, tremor and impairment of fine motor skills (Johannesen et al., 2018). Moreover, several mutations in SLC6A1 have very recently been linked to a higher risk for autism and schizophrenia (Rees et al., 2020; Satterstrom et al., 2020). In the electroencephalogram, most patients exhibit generalized epileptiform discharges, especially at a frequency of 2–4 Hz. A generalized background slowing can be detected in one third of the cases (Goodspeed et al., 2020).

The currently available data guiding clinical management of SLC6A1-related disorders is rather scarce despite the large unmet need for effective treatment strategies of patients suffering from these conditions. Johannesen et al. reported that 20 of 31 patients achieved some seizure relief, with valproic acid being the most effective drug (Johannesen et al., 2018). However, seizure control was not correlated with the cognitive outcome, and on top of the broad spectrum of unpleasant adverse effects of valproic acid, make this compound a suboptimal therapeutic choice. Notably, significant improvements have been observed in response to a ketogenic diet (Carvill et al., 2015; Palmer et al., 2016), an avenue worth delving into.

The exact prevalence of SLC6A1-related disorders is difficult to estimate. However, it is important to note that epidemiological data reported for other solute carriers, e.g. the glucose transporter 1 (GLUT-1, SLC2A1), which is also linked to epilepsy and other neurological conditions, indicate a frequency of GLUT-1 mutations of approximately 1:83,000 in the Danish population (Larsen et al., 2015).

### MOLECULAR TRAITS BEHIND SLC6A1 VARIANT PATHOPHYSIOLOGY: THE RULES AND LESSONS DRAWN FROM THE SLC6 RELATIVES

Disease mutations can impair protein folding and trap transporter proteins in the ER compartment, thus precluding their export and intracellular trafficking. Other mutations emanate structural defects and disrupt transport activity without altering cell surface expression of the resulting proteins. Putative effects of such loss-of-function hGAT-1 variants, as currently understood, are depicted in Figure 2. To date, dozens of pathological transporter variants have been verified as folding-deficient. The first reported case of a misfolded SLC6 transporter was a variant of the human norepinephrine transporter (NET, SLC6A2). A 33-year-old woman suffering from the autonomic disorder orthostatic intolerance was found to harbor a heterozygous A457P point mutation in the SLC6A2 gene (Shannon et al., 2000). The mutation compromised ER export, causing a substantial loss of cell surface expression. Moreover, it exerted a dominant-negative effect on the wild type transporter (i.e., product of the healthy allele) through formation of non-productive oligomeric complexes, targeted to degradative pathways (Hahn et al., 2003). This was consistent with the hypothesis that oligomer formation is a crucial requirement for ER export (Scholze et al., 2002). In DAT (SLC6A3), dozens of point mutations trigger infantile parkinsonism (Kurian et al., 2009; Ng et al., 2014). A vast majority of these induce DAT misfolding, i.e. the transporters accumulate as ER-resident core-glycosylated proteins (Mazhar Asjad et al., 2017). The genetic transmission is reported as autosomal recessive in all cases (i.e., patients are either homozygotes or compound heterozygotes), suggesting that clinical phenotypes only occur in the total absence of a functional DAT. Some variants exhibited a low residual

---

**TABLE 1** | (Continued) Human GAT-1 variants associated with neurological disorders.

| Variant     | Associated Phenotype(s)                                                                 | References                  |
|-------------|----------------------------------------------------------------------------------------|-----------------------------|
| K448*       | Epilepsy with myoclonic-atonic seizures, moderate ID (nonverbal), autism spectrum disorder, unsteady gait | Johannesen et al. (2018)    |
| D451G       | Moderate ID, autism spectrum disorder, speech delay and seizures                       | Bowling et al. (2017)       |
| G457Hfs*10  | Epilepsy with myoclonic-atonic seizures (evolving to atypical benign epilepsy with centrotemporal spikes), mild ID, unsteady gait/balance problems | Carvill et al. (2015), Johannesen et al. (2018) |
| S459R       | Generalized epilepsy, severe ID (almost nonverbal), aggressive behavior                 | Johannesen et al. (2018)    |
| W496*       | Generalized epilepsy, autism spectrum disorder, mild hypotonia                          | Mattison et al. (2018)      |
| V511M       | Generalized epilepsy, mild ID (verbal), ADHD                                           | Johannesen et al. (2018)    |
| W532*       | Epilepsy, language disorder, developmental delay, autism spectrum disorder, hypotonia, movement disorder | Kahen et al. (2021)         |
| QS34*       | Epilepsy with myoclonic-atonic seizures, mild ID, mild ataxia, dyskinesia              | Johannesen et al. (2018)    |
| GS50R       | Generalized epilepsy, autism spectrum disorder                                          | Wang et al. (2016), Mattison et al. (2018) |
| Rs666*      | Generalized epilepsy, learning disorder, non-specific dysmorphisms                      | Posar & Visconti (2019)     |

Pathogenic mutations in SLC6A1 listed with the associated clinical features and inheritance pattern.

---

Fischer et al. Human GAT-1 Variants in Disease
uptake: e.g., A314V-DAT retained 8% of wild type DAT uptake levels. In contrast to mutants that were completely devoid of uptake activity, this variant led to a later disease onset and a milder clinical course. Hence, residual activity of the mutant transporters relates to the onset and the severity of the disease symptoms (Ng et al., 2014). In the instance of the glycine transporter 2 (GLYT-2, SLC6A5), several mutations have been linked to hyperekplexia/startle disease (Rees et al., 2006; Carta et al., 2012). Most mutations are transmitted in a recessive manner. However, some dominantly-inherited mutations have also been reported. At least one of the identified variants (S510R-GLYT-2) is known to accumulate in the form of intracellular aggregates, indicative of a folding defect (Rees et al., 2006). In addition, mutations in CRT-1 (SLC6A8) cause ID and epilepsy (Salomons et al., 2001; Van De Kamp et al., 2014). Confocal microscopy experiments revealed that many of these variants are trapped in the ER, i.e. co-localized with the ER marker calnexin (El-Kasaby et al., 2019).

Folding-deficient mutants can be rescued by chemical or pharmacological chaperones (Chaudhuri and Paul, 2006). These small molecules stabilize the misfolded protein, promote folding and facilitate delivery to the required cellular locations (Loo and Clarke, 2007). Chemical chaperones such as glycerol, dimethyl sulfoxide and 4-phenylbutyric acid (4-PBA) enhance folding of many proteins (Perlmuter, 2002). Pharmacological chaperones bind directly to, and stabilize, their cognate target proteins and their action is restricted to specific target proteins. Prominent examples include migalastat and lumacaftor, used to treat Fabry disease (Germain et al., 2016) and cystic fibrosis (Wainwright et al., 2015), respectively. The first pharmacochaperone shown to be highly effective in the SLC6 family was (nor)ibogaine. We showed that ibogaine binds to the inward-facing transporter conformation and rescues the misfolded serotonin transporter (SERT, SLC6A4) mutant R607A/I608A-SERT, which harbors mutations in the ER-export motif (El-Kasaby et al., 2014; Montgomery et al., 2014). Introducing second site suppressor mutations, which trap SERT in the inward-facing state, also promoted surface expression of folding-deficient SERTs (Koban et al., 2015). Noribogaine and its congeners also rescued several misfolded parkinsonism-causing DAT variants (Beerepoot et al., 2016; Mazhar Asjad et al., 2017). Partial substrates like PAL1045 can rescue the starkly misfolded P601A/G602A-SERT (Bhat et al., 2017). Chemical chaperones such as 4-PBA rescued CRT-1 variants linked to ID (El-Kasaby et al., 2019). Moreover, heat shock protein (HSP) inhibitors proved efficient: the HSP70 inhibitor pifithrin-μ rescued misfolded DATs, while the HSP90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) sensitized misfolded SERTs to the pharmacochaperone action of noribogaine (Kasture et al., 2016; Mazhar Asjad et al., 2017). The action of HSP inhibitors can be rationalized: the folding trajectory is monitored by a relay of HSPs. These proteinaceous chaperones must be released for the protein cargo to exit the ER. Their inhibition relaxes the stringent ER quality control and promotes ER export (Freissmuth et al., 2017). Pharmacochaperoning is not limited to heterologous expression in cell lines; we also provided a proof-of-principle that folding-deficient DATs are amenable to rescue in vivo, in Drosophila melanogaster (Mazhar Asjad et al., 2017).

The above inferences may well echo onto the hGAT-1 epilepsy variants, considering the high phylogenetic similarity in the SLC6 family (Freissmuth et al., 2017; Bhat et al., 2021). As a matter of fact, it is striking that pathogenic mutations can occur at conserved/equivalent residues among members of the SLC6
transporter family. For instance, a substitution of alanine at position 275 in the human GLYT-2 to threonine (i.e. variant A275T-hGLYT-2, equivalent to A288-hGAT-1 shown in Figure 1) leads to hyperekplexia/startle disease. The molecular grounds for disease onset, discerned using electrophysiological measurements, revealed that A275T induces a reduction in Na+ ion affinity and in turn diminishes the voltage-sensitive glycine uptake (Carta et al., 2012). A similar scenario transpires for the recurring hGAT-1 variant G232V. In the human CRT-1, the substitution of the corresponding glycine residue by an arginine (i.e. variant G253R-hCRT-1) triggers ID accompanied by severe delay in speech and language development. Reportedly, the affected boy’s carrier mother (i.e. creatine transporter deficiency being an X-linked disease) also exhibited borderline intellectual functioning (Battini et al., 2011). At the molecular level, we found that the G253R mutation elicits its loss-of-function disease phenotype by triggering protein folding defects in the hCRT-1 protein, trapping the mutated transporter in the ER (El-Kasaby et al., 2019). Although the cell surface expression of this variant was restored upon treatment with the chemical chaperone 4-PBA or inhibitors of cell surface expression of this variant was restored upon treatment with the chemical chaperone 4-PBA or inhibitors of HSP 70 and 90 (pi plantin-µ and 17-DMAG, respectively), its creatine uptake activity was not salvaged to any appreciable level (El-Kasaby et al., 2019).

**ANIMAL MODELS IN EXPLORING SLC6A1 DISORDERS: AN EMPHASIS ON FRUIT FLIES**

The GABA transporter is evolutionarily highly conserved. SLC6A1 orthologs exist in organisms ranging from roundworms and fruit flies to zebrafish and mammals. Various animal models have been explored to understand the pathophysiological aspects of epilepsy (Engel and Wu, 1994; Avoli, 1995; Pavlidis and Tanouye, 1995; Lee and Wu, 2002; Noebels, 2003; Williams et al., 2004; Baraban et al., 2005). Reduced or altered GAT-1 functioning in mice results in absence seizures, and thalamic GAT-1, which exhibits marked astrocytic expression, is known to regulate absence seizures (Cope et al., 2009). A library of transgenic mice (expressing multiple GAT-1 variants) would be an ideal approach to study GAT-1 disease-associated pathological changes, as well as drug candidate screenings. However, establishing such libraries is not only laborious, but also logistically and financially challenging.

In contrast to their vertebrate counterparts, invertebrates, such as roundworms and fruit flies, possess only a single GABA transporter. As such, they provide a unique opportunity to study disease-relevant mutants in a high-throughput manner. We here focus on utilizing *Drosophila melanogaster* as a model organism to unravel the pathophysiological aspects of GAT-1 variants. These dew-loving fruit flies have remained an organism of choice in studies of conserved biological processes for over 100 years. This is largely on account of their short life cycle, ease of maintenance, cost-effectiveness and their rich genetic arsenal. Around 75% disease-related genes carry an ortholog in flies (Reiter et al., 2001). The ability to generate transgenic flies that express human proteins in a spatial and temporal manner, makes *Drosophila* ideal in examining human disorders (Rubin and Spradling, 1982; Brand and Perrimon, 1993; Gratza et al., 2015; Mazhar Asjad et al., 2017). *Drosophila* has gained much attention in studies of conserved solute carrier proteins (Thimgan et al., 2006; Kasture et al., 2016; 2017; 2018; 2019; Sucic et al., 2016). It recently proved to have great translational potential in the case of folding-impaired DAT variants (Mazhar Asjad et al., 2017). We, and others, have examined the trafficking and activity of dopamine transporter deficiency syndrome (DTDS)-linked mutants in *Drosophila* (Kasture et al., 2016; Mazhar Asjad et al., 2017; Aguilar et al., 2021). Drug screens carried out in *Drosophila* were led by data from *in silico* and *in vitro* experiments, and have also been validated in induced pluripotent stem cells (iPSCs) obtained from DTDS patients (Ng et al., 2021).

The *Drosophila* GAT (dGAT) is expressed exclusively on astrocytes (Stork et al., 2014). Surface dGAT expression is highly dynamic and regulated by metabotropic GABA receptor signaling (Muthukumar et al., 2014). The excitatory amino acid transporter, which takes up glutamate, is also exclusive to astrocytic expression in flies (Soustelle et al., 2002). The GAT-KO or null mutation in flies leads to embryonic lethality. However, this phenotype is resuciable via expression of dGAT in astrocytes (Stork et al., 2014). A knockdown of dGAT during
the development induces severe locomotor defects in fruit flies, at both larval and adult stages (Stork et al., 2014). One study reported that impaired glutamate/GABA/glutamine cycling in adult Drosophila astrocytes results in motor defects and greatly increases the recovery time from heat-induced seizures, both of which can be appreciably rescued by overexpressing dGAT in astrocytes (Mazaud et al., 2019). In other words, GAT expression, when modulated only in the adult stage, can affect the locomotor activity and seizure sensibility in flies. Similar to mammals, where GABA_B agonists induce absence seizures and GABA_B inhibitors block them, a reduction of astrocytic metabotropic GABA_B signaling ameliorates the seizure activity in flies (Muthukumar et al., 2014). The Drosophila model is not a new player in the epilepsy field: the role of diverse ion channels in the generation of epilepsy were discovered using fruit flies (Kuebler and Tanouye, 2000; Granetzky and Wu, 1982, reviewed in Granetzky, 2000; Song and Tanouye, 2008). Henceforth, Drosophila has remained the model organism of choice when it comes to defining the molecular underpinnings behind generalized epilepsy (Ghosh et al., 2018; Manivannan et al., 2021; Yap et al., 2021). A simplified illustration on the use of fruit flies in epilepsy-related research is shown in Figure 3. Upon mechanical agitation, by brief 10-s vortexing, Drosophila exhibit stereotypical seizure-like activity characterized by leg twitches, abdominal contractions, proboscis extensions and wing flapping, which is followed by paralysis, delayed spasms (recovery seizures) and recovery to normal posture. Genetic background largely affects the sensitivity to seizures and seizure-duration in flies, whereby bang-sensitive mutants exhibit longer recovery times. In addition to mechanical stimulus, seizure-like activity can also be induced by heat shock (i.e., exposure to high temperature), high-frequency electrical stimulation, and chemical treatment (i.e., picrotoxin feeding) (Granetzky and Wu, 1982; Pavlidis and Tanouye, 1995; Stilwell et al., 2006).

Flies are deemed an attractive model for high-throughput screening of antiepileptic drugs (Stilwell et al., 2006). dGAT and hGAT-1 show 52% sequence similarity, and remarkably, most of the disease-relevant amino acid residues are conserved among the two proteins. Novel gene editing tools such as CRISPR/Cas9 technique can be employed to create disease point mutations in the dGAT sequence (Lamb et al., 2017). Humanized flies expressing GAT-1 pathogenic variants could also be easily generated, and their trafficking through the secretory pathway and functioning at the plasmalemma subsequently examined in neuronal and astrocytic populations in flies. It is crucial to understand the fate of misfolded GAT-1 variants in GABAergic neurons and astrocytes. The mechanisms of how reduced (or totally absent) surface expression of GAT-1 affects the functional tripartite synapse can be addressed by assessing changes in synaptic connectivity (Shearin et al., 2018) and activity in flies (Macpherson et al., 2015). Flies also allow for inspecting whether the ER-retained fraction of GAT-1 proteins undergoes rapid clearance or imparts ER-stress (Ryoo et al., 2013). Additionally, a GABA biosensor can be utilized to evaluate the changing trends of extracellular GABA levels (Marvin et al., 2019), whilst GAT-1 activity can be assessed in a sensitized background for locomotor functioning and susceptibility to seizures.

**IS THE GAIN-OF-FUNCTION BRUNT OF THE GABAAERGIC SYSTEM TO BLAME?**

Evidently, the molecular rationale underlying SLC6A1-related disorders is not entirely clear. GAT-1 KO mice provided several valuable insights: 1) they are more sensitive to pentylenetetrazole-induced seizures and display spontaneous spike-and-wave discharges (SWD), which are typically associated with absence seizures (Chiu et al., 2005; Cope et al., 2009). 2) They show an increased extrasynaptic GABA_\text{A} receptor-mediated tonic conductance in thalamic, cerebellar and cortical brain regions (Chiu et al., 2005; Bragina et al., 2008; Cope et al., 2009). In other words, the tonic inhibition imparted by peri- or extrasynaptic GABA_\text{A} receptors is altered in GAT-1 KO mice. 3) Aberrant phasic inhibition is observed in thalamic and cortical regions (Bragina et al., 2008; Cope et al., 2009). This observation is contrary to other absence seizures models, where phasic inhibition remained unchanged with the tonic inhibition only being affected (Cope et al., 2009).

The role of thalamic GAT-1 in modulating absence seizure was studied in wild type Wistar rats by intrathalamic administration of the selective GAT-1 inhibitor NO-711. This inhibition induced absence seizures and was rescued by ethosuximide, indicating that thalamic GAT-1 is crucial in modulating absence seizures (Cope et al., 2009). Abundantly available extracellular GABA acts on extrasynaptic GABA_\text{A} receptors in the thalamocortical region to induce absence seizure. The \( \delta \) subunit of extracellular GABA_\text{A} receptors is linked to aberrant tonic inhibition, and gain-of-function mutations in the \( \text{GABRD} \) gene encoding the \( \delta \) subunit, mimic the phenotypic spectrum of patients harboring SLC6A1 disease mutations (Ahring et al., 2021). Furthermore, GABA_B receptor agonists are known to induce absence seizures and can even facilitate the extrasynaptic GABA_\text{A} receptor-mediated tonic inhibition (Cope et al., 2009). The GABA_B receptor-mediated absence seizures are linked to the activation of low-voltage-activated (T-type) calcium channels in the thalamus (Kim et al., 2001). Whether T-type calcium ion channels are affected in SLC6A1-related disorders remains unclear. In a nutshell, the thalamus is a region critical to controlling absence seizures, with GAT-1 exclusively expressed on astrocytes, and reduced GAT-1 function and/or enhanced GABA_A and GABA_B receptor tonic activation precipitating in absence seizures.

The mutations in SLC6A1 reduce or abolish GABA uptake and in a clinical setting they appear to phenocopy the GAT-1 KO mice behavioural defects. All known mutations linked to SLC6A1-related disorders exhibit variable degrees of ER retention, suggesting that the GAT-1-mediated uptake is partly or completely affected (Mermer et al., 2021). As a consequence, if the downstream signalling mediated by
variants associated with DTDS. Very recently, gene therapy was employed to restore DAT expression and ameliorate pathophysiology in iPSC and mouse models of this condition (Ng et al., 2021). With respect to GAT-1-linked syndromes, the epileptogenic mechanisms are still not utterly clear-cut. While some mutations appear to impair protein folding and/or trafficking, others trigger structural/conformational defects, with both scenarios irrefutably ending in deficient GABA transport. State-of-the-art computer simulation models can serve as another expedient complimentary approach in exploring mutation-specific ramifications at the atomic level, backing the biochemical and pharmacological data. Seminal discoveries from studies on other SLC6 family members (e.g., SERT, DAT and CRT-1) provide ample succour in facing the challenges of GAT-1 disease variants, and grant an optimistic outlook on finding the cure. In view of our recent work, we begin to appreciate how small molecules can become auspicious therapeutic agents in tackling great medical obstacles.

CONCLUDING REMARKS

The transporter research community is faced with an escalating amount of reports linking pathological conditions in people with specific variants in transporter genes. We here aimed to convey the impending clinical impact of probing the molecular core of such disorders, ideally at the level of each individual mutation. The pharmacotherapeutic potential of such in-depth studies is immense: it can translate into shaping the long-awaited strategies for adequate treatment of severe diseases, such as epilepsy, ID or parkinsonism, to name just a few. A systematic and rational search for novel therapeutic options by pharmacological means, i.e., treatment with small molecules (e.g., chemical/pharmacological chaperones or allosteric modulators) to restore the activity of dysfunctional variants has proven worthwhile in the paradigm of DAT variants associated with DTDS. Very recently, gene therapy was

REFERENCES

Aguilar, J. I., Cheng, M. H., Font, J., Schwartz, A. C., Ledwitch, K., Duran, A., et al. (2021). Psychomotor Impairments and Therapeutic Implications Revealed by a Mutation Associated with Infantile Parkinsonism-Dystonia. Elife 10, e66039. doi:10.7554/eLife.66039
Ahring, P. K., Liao, Y. W. Y., Gardella, E., Johannesen, K. M., Krey, I., Selmer, K. K., et al. (2021). Gain-of-function Variants in GABRD Reveal a Novel Pathway for Neurodevelopmental Disorders and Epilepsy. Brain 391, awab391. doi:10.1093/brain/awab391
Asjad, H. M. M., Kasture, A., El-Kasaby, A., Sackel, M., Hummel, T., Freissmuth, M., et al. (2017). Pharmacochaperoning in a Drosophila Model System Rescues Human Dopamine Transporter Variants Associated with Infantile/juvenile Parkinsonism. J. Biol. Chem. 292, 19250–19265. doi:10.1074/jbc.M117.797092
Avoli, M. (1995). Feline Generalized Penicillin Epilepsy. Ital. J. Neuro Sci. 16, 79–82. doi:10.1007/BF02229078
Awapara, J., Landua, A. J., Fuerst, R., and Seale, B. (1950). FREE γ-AMINOBUTYRIC ACID IN BRAIN. J. Biol. Chem. 187, 35–39. doi:10.1016/S0021-9258(19)50926-7
Baraban, S. C., Taylor, M. R., Castro, P. A., and Baier, H. (2005). Pentylenetetrazole Alters Behavior, Neural Activity and C-Fos Expression. Neuroscience 131, 759–768. doi:10.1016/j.neuroscience.2004.11.031
Battini, R., Chilos, A. M., Casarano, M., Moro, F., Comparini, A., Alessandri, M. G., et al. (2011). Language Disorder with Mild Intellectual Disability in a Child Affected by a Novel Mutation of SLC6A8 Gene. Mol. Genet. Metab. 102, 153–156. doi:10.1016/j.ymgme.2010.11.005
Beerepoot, P., Lam, V. M., and Salaphour, A. (2016). Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells. J. Biol. Chem. 291, 22053–22062. doi:10.1074/jbc.M116.749119

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

FUNDING

The authors acknowledge financial support from the Austrian Science Fund (FWF project P31255-B27 to SS).
Lamb, A. M., Walker, E. A., and Wittkopp, P. J. (2017). Tools and Strategies for Scarless Allele Replacement in Drosophila Using CRISPR/Cas9. Fly 11, 53–64. doi:10.1093/jnci/djx394

Landrum, M. J., Lee, J. M., Benson, M., Brown, G. R., Chao, C., Chitipiralla, S., et al. (2018). ClinVar: Improving Access to Variant Interpretations and Supporting Evidence. Nucleic Acids Res. 46, D1062–D1067. doi:10.1093/NAR/GKX1153

LaRoche, S. M., and Helmers, S. L. (2004). The New Antiepileptic Drugs. J. Neurosci. 24, 13–19. doi:10.1523/JNEUROSCI.22-04-01105.2002

Liu, G.-X., Cai, G.-Q., Sheng, Z.-J., Jiang, J., Mei, Z., et al. (2007b). Reduced Anxiety and Depression-like Behaviors in Mice Lacking GABA Transporter Subtype 1. J. Neurosci. 27, 599–625. doi:10.1523/JNEUROSCI.26-03-05810.1995

Lucariello, M., Vidal, E., Saez, R., Leite, M., Kawashima, T., Jensen, T. P., et al. (2016). Dynamic Labelling of Neural Connections in Multiple Colours by Trans-synaptic Fluorescence Complementation. Nat. Commun. 6, 1–9. doi:10.1038/ncomms10024

Marvin, J. S., Shimoda, Y., Magloire, V., Leite, M., Kawashima, T., Jensen, T. P., et al. (2019). A Genetically Encoded Fluorescent Sensor for In Vivo Imaging of GABA. Nat. Methods 16, 763–770. doi:10.1038/s41592-019-0471-2

Mattison, K. A., Butler, K. M., Inglis, G. A. S., Dayan, O., Boussidan, H., Sheng, Z.-J., Cai, Y.-Q., Jiang, J., Mei, Z., et al. (2007a). Reduced Anxiety and Depression-like Behaviors in Mice Lacking GABA Transporter Subtype 1. J. Neurosci. 27, 599–625. doi:10.1523/JNEUROSCI.26-03-05810.1995

Moss, F. J., Immokhuede, P. I., Scott, K., Hu, J., Jankowsky, J. L., Quick, M. W., et al. (2019). GABA Transporter Function, Oligomerization State, and Anchoring: Correlates with Subcellularly Resolved FRET. J. Gen. Physiol. 134, 489–521. doi:10.1085/jgp.200910314

Montgomery, T. S., Steinkeller, T., Susic, S., Koban, F., Schüchner, S., Ogris, E., et al. (2014). Axonal Targeting of the Serotonin Transporter in Cultured Rat Dorsal Raphe Neurons Is Specified by SEC24C-Dependent Export from the Endoplasmic Reticulum. J. Neurosci. 34 (18), 6344–6351. doi:10.1523/JNEUROSCI.2911-13.2014

Ng, J., Barral, S., de la Fuente Barrigon, C., Lignani, G., Erdem, F. A., Wallings, R., et al. (2021). Gene Therapy Restores Dopamine Transporter Expression and Ameliorates Pathology in iPSC and Mouse Models of Infantile Parkinsonism. Sci. Transl. Med. 13, eawz1564. doi:10.1126/scitransmed.awz1564

Ng, J., Dea, I. S. R., and Kurian, M. A. (2014). Clinical Features and Pharmacotherapy of Childhood Monoamine Neurotransmitter Disorders. Pediatr. Drugs 16, 275–291. doi:10.1007/s40272-014-0079-Z

Norwood, J. L. (2003). The Biology of Epilepsy Genes. Annu. Rev. Neurosci. 26, 599–625. doi:10.1146/ANNUREV.NEURO.26.010302.081210

Perlmutter, D. H. (2002). Chemical Chaperones: a Pharmacological Strategy for Disorders of Protein Folding and Trafficking. Pediatr. Res. 52, 832–836. doi:10.1203/00006450-200212000-00004

Poliquin, S., Hughes, I., Shen, W., Mermer, F., Wang, J., Mack, T., et al. (2021). Genetic Mosaicism, Intrafamilial Phenotypic Heterogeneity, and Molecular Defects of a Novel Missense SLC6A1 Mutation Associated with Epilepsy and ADHD. Exp. Neurol. 342, 113723. doi:10.1016/j.expneurol.2021.113723

Posar, A., and Visconti, P. (2019). Mild Phenotype Associated with SLC6A1A Gene Mutation: A Case Report with Literature Review. J. Pediatr. Neurosci. 14, 100–102. doi:10.4103/jpn.JPN_2_19

Quick, M. W., Hu, J., Wang, D., and Zhang, H.-Y. (2004). Regulation of a γ-Aminobutyric Acid Transporter by Reciprocal Tyrosine and Serine Phosphorylation. J. Biol. Chem. 279, 15961–15967. doi:10.1074/jbc.M309024200

Roberts, E., and Frankel, S. (1950). N, N-Dimethylglycine Decarboxylase. J. Biol. Chem. 335, 329–334. doi:10.1016/S0021-9258(05)80022-7

Ryoo, H. D., Li, J., and Kang, M.-J. (2013). Drosophila XBP1 Expression Reporter Neurons_are_partially_activated_in_the_Giant_Fiber_Sympathetic_System. J. Neurosci. 33, 15374–15389. doi:10.1523/JNEUROSCI.3424-13.2013

Salm, P., Tomwe, M. C., Pardal, P. L., Pelletier, R. C., Genetti, C. A., Shi, J., et al. (2016). SLC6A1 Mutation and Ketogenic Diet in Epilepsy with Myoclonic-Atonic Seizures. Pediatr. Neurol. 64, 77–79. doi:10.1016/j.pediatrneurol.2016.07.012

Snaith, R. J., and Davies, J. H. (2007). The Role of SLCT2A1 Variants in Schizophrenia. Nat. Neurosci. 10, 558–565. doi:10.1038/nn.1847

Soomro, A., and Visconti, P. (2012). Range of Genetic Mutations Associated with Severe Non-syndromic Sporadic Intellectual Disability: An Exome Sequencing Study. The Lancet 380, 1674–1682. doi:10.1016/S0140-6736(12)64180-9

Steffy, R., Dea, I. S. R., and Kurian, M. A. (2014). Clinical Features and Pharmacotherapy of Childhood Monoamine Neurotransmitter Disorders. Pediatr. Drugs 16, 275–291. doi:10.1007/s40272-014-0079-Z

Vaninov, N. S., Rovers, I., Smal, N., Myers, C. T., Turkdogan, D., Roelens, F., et al. (2021). De Novo FZR1 Loss-Of-Function Variants Cause Developmental and Epileptic Encephalopathies. Brain 2021, awab409. doi:10.1093/brain/awab409

Vidal, E., Saez, R., Leite, M., Kawashima, T., Jensen, T. P., et al. (2019). A Genetically Encoded Fluorescent Sensor for In Vivo Imaging of GABA. Nat. Methods 16, 763–770. doi:10.1038/s41592-019-0471-2

Wallers, R., Boivin, F. J., and Bier, E. (2001). A Systematic Analysis of Human Disease-Associated Gene Sequences in Drosophila melanogaster. Genome Res. 11, 1114–1125. doi:10.1101/GR.169101

Wilkinson, D. J., and Draguhn, A. (2012). GABA Metabolism and Transport: Effects on Synaptic Efficiency. Neural Plasticity 2012, 1–12. doi:10.1155/2012/805830

Wilson, S. L., Madsen, K. K., Schousboe, A., and White, H. S. (2012). Glutamate and GABA Synthesis, Release, Transport and Metabolism as Targets for Seizure Control. Neurochem. Int. 61, 546–558. doi:10.1016/j.neint.2012.02.013

Zhu, Y., Schouenborg, J., and Brierley, P. (2013). The Role of SLCT2A1 Variants in Schizophrenia. Nat. Neurosci. 10, 558–565. doi:10.1038/nn.1847

Zinchenko, V., et al. (2018). SLC6A1 Variants Identified in Epilepsy Patients. J. Neurosci. 38, 135–141. doi:10.1523/JNEUROSCI.15-11-07734.1995
Salomons, G. S., Van Dooren, S. J. M., Verhoeffen, N. M., Cecil, K. M., Ball, W. S., Degrauw, T. J., et al. (2001). X-linked Creatine-Transporter Gene (SLC6A8) Defect: A New Creatine-Deficiency Syndrome. Am. J. Hum. Genet. 68, 1497–1500. doi:10.1086/320595

Sanders, S. J., Murtha, M. T., Gupta, A. R., Murdoch, J. D., Raubeson, M. J., Willeys, A. J., et al. (2012). De novo mutations revealed by Whole-Exome Sequencing Are Strongly Associated with Autism. Nature 485, 237–241. doi:10.1038/nature10945

Satterstrom, F. K., Kosmicki, J. A., Wang, J., Breen, M. S., De Rubeis, S., An, J. Y., Schousboe, A., Madsen, K. K., Barker-Haliski, M. L., and White, H. S. (2014). The Scholze, P., Freissmuth, M., and Sitte, H. H. (2002). Mutations within an

Waagepetersen, H. S., Sonnewald, U., and Schousboe, A. (1999). The GABA Paradox. J. Neurochem. 73 (4), 1333–1342. doi:10.1046/j.1471-4159.1999.733135.x

Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., et al. (2015). Lumacator-Ivacator in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N. Engl. J. Med. 373, 220–231. doi:10.1056/nejmoa1405947

Wang, J., Poliquin, S., Mermer, F., Eissmann, J., Delpire, E., Wang, J., et al. (2020). Endoplasmic Reticulum Retention and Degradation of a Mutation in SLC6A1 Associated with Epilepsy and Autism. Mol. Brain 13 76. doi:10.1186/s13041-020-00612-6

Wang, T., Guo, H., Xiong, B., Stessman, H. A. F., Wu, H., Coe, B. P., et al. (2016). De Novo genic Mutations Among a Chinese Autism Spectrum Disorder Cohort. Nat. Commun. 7, 13316. doi:10.1038/ncomms13316

Williams, S. N., Locke, C. J., Braden, A. L., Caldwell, K. A., and Caldwell, G. A. (2004). Epileptic-like Convulsions Associated with LIS-1 in the Cytoskeletal Control of Neurotransmitter Signaling in Caenorhabditis elegans. Hum. Mol. Genet. 13, 2043–2059. doi:10.1093/hmg/ddh209

Wu, Y., Wang, W., Díez-Sampedro, A., and Richenberg, G. B. (2007). Nonvesicular Inhibitory Neurotransmission via Reversal of the GABA Transporter GAT-1. Neuron 56, 851–865. doi:10.1016/j.neuron.2007.10.021

Xu, Y. F., Cai, Y. Q., Cai, G. Q., Jiang, J., Sheng, Z. J., Wang, Z. G., et al. (2008). Hypogalactia in Mice Lacking GABA Transporter Subtype 1. J. Neurosci. Res. 86, 465–470. doi:10.1002/jnr.21199

Xu, Y.-F., Cariaga, W. A., and Ribak, C. E. (1997). Immunoreactivity for GABA Transporter Distribution in the Monkey Cerebral Neocortex and hippocampus. J. Neurochem. 66, 296–306. doi:10.1002/jnc.470660124

Xu, Y. F., Cariaga, W. A., and Ribak, C. E. (1997). Immunoreactivity for GABA Plasma Membrane Transporter, GAT-1, in the Developing Rat Cerebral Cortex: Transient Presence in the Somata of Neocortical and Hippocampal Neurons. Dev. Brain Res. 99, 1–19. doi:10.1016/s0165-3806(96)00192-7

Xu, Y. F., Cariaga, W. A., and Ribak, C. E. (1997). Immunoreactivity for GABA Plasma Membrane Transporter, GAT-1, in the Developing Rat Cerebral Cortex: Transient Presence in the Somata of Neocortical and Hippocampal Neurons. Dev. Brain Res. 99, 1–19. doi:10.1016/s0165-3806(96)00192-7

Yap, Z. Y., Efthymiou, S., Seiffert, S., Vargas Parra, K., Lee, S., Nasca, A., et al. (2021). Bi-allelic Variants in OGDHL Cause a Neurodevelopmental Spectrum Disease Featuring Epilepsy, Hearing Loss, Visual Impairment, and Ataxia. Am. J. Hum. Genet. 108, 2368–2384. doi:10.1016/j.ajhg.2021.11.003

Yuen, R. K., Merico, D., Cao, H., Pellecchia, G., Alipanahi, B., Thiruvahindrapuram, B., et al. (2016). Genome-wide Characteristics of De Novo Mutations in Autism. Npj Genomic Med. 1, 16027. doi:10.1038/npjgenmed.2016.27

Zhou, Y., and Danbolt, N. C. (2013). GABA and Glutamate Transporters in Brain. Front. Endocrinol. 4, 165. doi:10.3389/fendo.2013.00165

Zhou, Y., Homlseth, S., Hua, R., Lehre, A. C., Olofsson, A. M., Poblete-Naredo, I., et al. (2012). The Betaine-GABA Transporter (BGT1, Slc6a12) Is Predominantly Expressed in the Liver and at Lower Levels in the Kidneys and at the Brain Surface. Am. J. Physiology-Renal Physiol. 302, F316–F328. doi:10.1152/ajpregu.00464.2011

Zhu, X.-M., and Ong, W.-Y. (2004). A Light and Electron Microscopic Study of Betaine/GABA Transporter Distribution in the Monkey Cerebral Neocortex and hippocampus. J. Neurocytol. 33, 233–240. doi:10.1023/B:NEUR.0000036098.66675.90

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Fischer, Kasture, Hummel and Sucic. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.